bullish
How High Can CureVac Stock Go After Blockbuster IPO? We Update Bull Case Scenario to $80 Per Share
578 Views17 Aug 2020 21:37
CureVac stock closed at $55.90 per share during the first trading day, the best performance among biotech IPOs this year. Since the beginning of...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Rising
Andrei Zakharov
Covering IPOs, Healthcare and Technology Stocks
Price Chart(Sign Up to Access)
- Success of Moderna’s COVID-19 Vaccine May Give a Boost to Stocks of Messenger RNA Companies13 Nov 2020
- Expecting First Results From Phase 1 Clinical Trials Of COVID-19 Vaccine In October28 Sep 2020
- CureVac May Supply ~225M of Potential COVID-19 Vaccine Doses. A Big Win Over Moderna and BioNTech21 Aug 2020
- CureVac IPO. Beating Rivals to Secure a COVID-19 Vaccine Based on MRNA Technology14 Aug 2020
x